Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
1999 2
2000 4
2001 2
2002 5
2003 6
2004 7
2005 6
2006 2
2007 6
2008 4
2009 4
2010 4
2011 10
2012 3
2013 6
2014 6
2015 4
2016 2
2017 4
2018 6
2019 3
2020 2
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24586176

96 results

Results by year

Filters applied: . Clear all
Page 1
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C, Assoumou L, Ghosn J, Duvivier C, Peytavin G, Ait-Arkoub Z, Molina JM, Costagliola D, Katlama C, Calvez V, Marcelin AG. Soulié C, et al. AIDS. 2009 Jul 31;23(12):1605-8. doi: 10.1097/QAD.0b013e32832d9031. AIDS. 2009. PMID: 19487903 Clinical Trial.
New antiretroviral drugs.
Gulick RM. Gulick RM. Clin Microbiol Infect. 2003 Mar;9(3):186-93. doi: 10.1046/j.1469-0691.2003.00570.x. Clin Microbiol Infect. 2003. PMID: 12667250 Free article. Review.
The development of anti-HIV-1 drugs.
Lu XF, Chen ZW. Lu XF, et al. Yao Xue Xue Bao. 2010 Feb;45(2):165-76. Yao Xue Xue Bao. 2010. PMID: 21348415 Review.
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
Wirden M, Delaugerre C, Marcelin AG, Ktorza N, Ait Mohand H, Dominguez S, Schneider L, Ghosn J, Pauchard M, Costagliola D, Katlama C, Calvez V. Wirden M, et al. Antimicrob Agents Chemother. 2004 Feb;48(2):644-7. doi: 10.1128/AAC.48.2.644-647.2004. Antimicrob Agents Chemother. 2004. PMID: 14742228 Free PMC article. Clinical Trial.
Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy.
Pasternak AO, Vroom J, Kootstra NA, Wit FW, de Bruin M, De Francesco D, Bakker M, Sabin CA, Winston A, Prins JM, Reiss P, Berkhout B; Co-morBidity in Relation to Aids (COBRA) Collaboration. Pasternak AO, et al. Elife. 2021 Aug 13;10:e68174. doi: 10.7554/eLife.68174. Elife. 2021. PMID: 34387543 Free PMC article.
96 results